{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:28Z","timestamp":1786977868176,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2016,12,15]]},"abstract":"<jats:p>Cutaneous malignant melanoma (CMM) incidence is increasing globally, making a thorough understanding of the disease and its outcomes essential for optimizing care even more urgent. In this population\u2010based, retrospective study, we investigated stage\u2010specific survival and recurrence\/progression rates of CMM among patients diagnosed in Stockholm County Council during 2005\u20132012, before the wide introduction of targeted therapy. A total of 3,554 CMM patients from the Stockholm Melanoma Register were included. Information on comorbidities, progression, death, and treatments was obtained from nationwide registers and hospital electronic medical records. Unadjusted 5\u2010year survival varied from 91.4% for stage I to 24.6% for stage IV patients. Stage, age and gender were predictors of survival, with gender an independent predictor of survival for stages IA and IIA. 74.6% of patients remained recurrence\/progression\u2010free during follow\u2010up, with 5\u2010year recurrence\/progression\u2010free survival rates varying from 85.3% to 12.9% among stages I and IV patients, respectively. In addition to stage, male gender, and age, circulatory system comorbidities increased the risk for recurrence\/progression. No statistically significant differences in progression rate for operated and non\u2010operated patients could be detected, possibly due to high rate (98.9%) of surgery. Our estimates of survival and recurrence rates are consistent with historical and global expectations and can serve as a baseline to gauge population\u2010level improvements with use of novel melanoma treatments.<\/jats:p>","DOI":"10.1002\/ijc.30407","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T11:25:35Z","timestamp":1472210735000},"page":"2722-2729","source":"Crossref","is-referenced-by-count":63,"title":["Epidemiology of cutaneous melanoma in Sweden\u2014Stage\u2010specific survival and rate of recurrence"],"prefix":"10.1002","volume":"139","author":[{"given":"Julia","family":"Rockberg","sequence":"first","affiliation":[{"name":"Pygargus AB\/IMS Health Sweden AB Pyramidv\u00e4gen 7 Solna Sweden 169 56"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna M.","family":"Amelio","sequence":"additional","affiliation":[{"name":"Amgen Inc, Uxbridge Business Park Uxbridge UK UB8 1DH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliki","family":"Taylor","sequence":"additional","affiliation":[{"name":"Amgen Inc, Uxbridge Business Park Uxbridge UK UB8 1DH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"J\u00f6rgensen","sequence":"additional","affiliation":[{"name":"Pygargus AB\/IMS Health Sweden AB Pyramidv\u00e4gen 7 Solna Sweden 169 56"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ragnhammar","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet, Karolinska University Hospital Solna Sweden 171 76"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hansson","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet, Karolinska University Hospital Solna Sweden 171 76"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12492"},{"key":"e_1_2_9_3_1","first-page":"13","volume-title":"Skin cancer\u2014a world\u2010wide perspective","author":"Whiteman D","year":"2011"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13483"},{"key":"e_1_2_9_5_1","volume-title":"Cancer incidence and mortality worldwide: IARC CancerBase No. 10","year":"2010"},{"key":"e_1_2_9_6_1","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli M","year":"2014","journal-title":"In Vivo"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3635"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05661"},{"key":"e_1_2_9_9_1","first-page":"346","article-title":"Current and future roles of targeted therapy and immunotherapy in advanced melanoma","volume":"20","author":"Olszanski AJ.","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2010.09.007"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310460"},{"key":"e_1_2_9_13_1","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia S","year":"2009","journal-title":"Oncology"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.02.005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12236"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.10.010"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27616"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.12.006"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.7564"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.1884"},{"key":"e_1_2_9_22_1","unstructured":"Regionala cancercentrum i samverkan. Nationell kvalitetsrapport f\u00f6r diagnos\u00e5r 2010\u20132013 fr\u00e5n Nationella hudmelanomregistret. September2014.http:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/hud\/kvalitetsregister\/20140929_melanom_rapport_2010-2013.pdfAccessed July 2016."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701785533"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30103"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-1-20"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.170"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.013"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.42"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0584"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02305762"},{"key":"e_1_2_9_31_1","first-page":"569","article-title":"Identifying predictive factors in melanoma progression","volume":"5","author":"Dabrowska DM","year":"1998","journal-title":"Oncol Rep"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21224"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.1335"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328337fe8f"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.001183"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004070"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20303"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802247664"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60269-X"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.30407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.30407","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.30407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:26:35Z","timestamp":1696371995000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.30407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12,15]]}},"alternative-id":["10.1002\/ijc.30407"],"URL":"https:\/\/doi.org\/10.1002\/ijc.30407","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]}}}